gms | German Medical Science

Artificial Vision 2017

The International Symposium on Visual Prosthetics

01.12. - 02.12.2017, Aachen

Visual function performances and outcomes of patients with some residual vision implanted with the Argus II retinal prosthesis

Meeting Abstract

Search Medline for

  • Marine Flourence - Second Sight Medical Products, Lausanne, Switzerland
  • A. Lesimple - Second Sight Medical Products, Lausanne, Switzerland
  • Argus II study group - Second Sight Medical Products, Lausanne, Switzerland

Artificial Vision 2017. Aachen, 01.-02.12.2017. Düsseldorf: German Medical Science GMS Publishing House; 2017. Doc17artvis29

doi: 10.3205/17artvis29, urn:nbn:de:0183-17artvis291

Published: November 30, 2017

© 2017 Flourence et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 License. See license information at http://creativecommons.org/licenses/by/4.0/.


Outline

Text

Objective: To focus on the visual function and outcomes of the patients with some residual vision implanted with the Argus II Retinal Prosthesis.

Materials and Methods: Two groups of patients were identified (patients without and with some residual vision) and the functional vision of the two groups were measured with two visual function tests (Square Localization and Direction of Motion) that were designed to evaluate a patient’s ability to locate an object and determine the direction of an object moving in the visual field. Daily life’s outcomes of these two groups of patients were based on the Functional Low-Vision Observer Rated Assessment (FLORA).

Results: The analysis focused on patients implanted with residual vision compared to patients without residual vision and the results show that the Argus II system gives benefits to both group of patients in terms of performances on the visual function tests and also in terms of mobility and daily living.

Discussion: The investigation demonstrates that patients with residual vision are able to combine the artificial vision and their own residual vision, allowing them to have better performances than patients with no residual vision in their daily living.